Verastem Oncology to Present Abstracts at AACR 2026 Meeting
Verastem Oncology Highlights Promising Preclinical Data and Multiple Abstract Presentations at AACR 2026 Verastem Oncology has announced the acceptance of multiple late-breaking and regular abstracts for presentation at the AACR Annual Meeting 2026, scheduled to take place from April 17–22,…
WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership
WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual…
Johnson & Johnson Secures FDA Approval for TECNIS PureSee Intraocular Lens to Improve Cataract Vision in the U.S.
Johnson & Johnson Secures U.S. Food and Drug Administration Approval for TECNIS PureSee Intraocular Lens, Expanding Vision Care Options for U.S. Cataract Patients Johnson & Johnson announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth…
Eli Lilly and Company Issues Safety Warning on Tirzepatide Compounded with Vitamin B12
Eli Lilly and Company Issues Open Letter Warning About Potential Patient Safety Risks of Tirzepatide Compounded with Vitamin B12 Lilly is issuing a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. As part of…
GoodRx Partners with Viatris to Provide Up to 85% Savings on Brand Medications
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications GoodRx the leading platform for prescription savings in the U.S., announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established…
Planet DDS 2026 Dental Outlook Reports More New Patients and Fewer No-Shows Across the Industry
Planet DDS 2026 Dental Outlook Shows More New Patients, Fewer No-Shows Across the Industry Planet DDS, a leading provider of cloud-based, enterprise-grade dental software solutions, announced the release of its 2026 Dental Industry Outlook, an annual benchmark report designed to help…
GeneDx Exome & Genome Testing Linked to $80K Savings and Better Outcomes
GeneDx Study Shows Significant Healthcare Cost Savings and Improved Outcomes for Children After Genomic Testing A new real-world data study presented by GeneDx has revealed that genomic testing can dramatically reduce healthcare costs and improve clinical outcomes for children with…
InterSystems Appoints Tim Ferris as Vice President of Healthcare Practice
InterSystems Appoints Tim Ferris as Vice President of Healthcare Practice InterSystems, a global data technology company that supports more than one billion health records worldwide, has announced the appointment of Tim Ferris as Vice President of its Healthcare Practice. The…
C2N Diagnostics Expands to South Korea with BeauBrain Partnership for Precivity™ Tests
C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests for Alzheimer’s Diagnosis Specialty diagnostics company C2N Diagnostics has announced a strategic partnership with South Korea–based healthcare firm BeauBrain Healthcare to introduce…
United Therapeutics Corporation Publishes TETON-2 Phase 3 Trial Results
United Therapeutics Corporation Shares TETON-2 Phase 3 Trial Findings in The New England Journal of Medicine United Therapeutics Corporation announced that the complete findings from its Phase 3 TETON-2 clinical trial evaluating nebulized Tyvaso® (treprostinil) inhalation solution for the treatment…
Precision BioSciences Secures U.S. Patent Allowances for PBGENE-HBV Program
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received…
Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumor Treatment
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…